SEPSF.US Asep Medical Holdings Inc
- Market cap
- USD 173K
- P/E
- -
- P/B
- 0.56x
- ROE
- -57.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is SEPSF.US undervalued?
Graham numberThe Graham number of Asep Medical Holdings Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Asep Medical Holdings Inc fundamental analysis
No fundamental analysis for Asep Medical Holdings Inc yet.
Asep Medical Holdings Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Asep Medical Holdings Inc
ASEP Medical Holdings Inc., together with its subsidiaries, engages in the acquisition of research and development assets, technologies, and businesses in the area of life sciences and medical diagnostics. It offers peptide technologies that cover therapeutic applications, including bacterial biofilm infections, anti-inflammatory, antibiotic synergy, and immune modulating; diagnostic kits for predicting the onset of severe sepsis; and medical devices with anti-microbial and …
Full company profileAsep Medical Holdings Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Asep Medical Holdings Inc annual financial statements (CAD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 61.2K | - | 0.00 | 0.00 | 21.1K | 336K | 290K |
| Gross Profit | 6.16K | -26.5K | -177K | -155K | -114K | -374K | -138K |
| Operating Income | -353.00 | -28.1K | -1.98M | -5.44M | -7.72M | -2.56M | -1.62M |
| EBITDA | - | 396.00 | -1.92M | -3.33M | -8.14M | -1.85M | -1.20M |
| Net Income | -353.00 | -28.1K | -2.20M | -4.52M | -8.23M | -4.91M | -1.76M |
| EPS | 0.00 | 0.00 | -0.04 | -0.08 | -0.13 | -0.48 | -0.12 |
| Balance Sheet | |||||||
| Total Assets | 2.59K | 11.0K | 30.7M | 27.1M | 25.6M | 8.71M | 8.54M |
| Total Liabilities | 125K | 162K | 144K | 528K | 3.05M | 4.38M | 3.57M |
| Shareholders' Equity | -122K | -151K | 18.3M | 15.5M | 12.6M | 2.33M | 3.05M |
| Cash & Short-term Investments | 534.00 | 8.47K | 5.29M | 2.13M | 64.7K | 154K | 76.4K |
| Total Debt | 111K | 141K | - | - | 20.3K | 230K | 178K |
| Cash Flow | |||||||
| Operating Cash Flow | -48.0K | -22.1K | -1.19M | -3.61M | -2.71M | -1.02M | -960K |
| Capital Expenditure | 0.00 | 0.00 | 116K | 435.00 | 4.47K | 4.12 | 8.26 |
| Free Cash Flow | -48.0K | -22.1K | -1.31M | -3.61M | -2.72M | -1.02M | -960K |
| Ratios | |||||||
| ROE | - | - | -12.0% | -29.3% | -65.2% | -211.2% | -57.6% |
| ROA | -13.6% | -255.9% | -7.2% | -16.7% | -32.1% | -56.4% | -20.6% |
| Net Profit Margin | -0.6% | - | - | - | -38,918.3% | -1,459.7% | -606.3% |
| Debt to Equity | - | - | - | - | 0.00x | 0.10x | 0.06x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Asep Medical Holdings Inc dividends
Asep Medical Holdings Inc has not paid dividends in the last 7 fiscal years.
Last stock split: 1:10 on Apr 17, 2025.
Who owns Asep Medical Holdings Inc
- Insiders 18.99%
- Institutions 0.00%
- Public & others 81.01%
- Shares outstanding 15.9M
- Free float 7.74M
Asep Medical Holdings Inc company profile
- Company name
- Asep Medical Holdings Inc
- Ticker
- SEPSF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 3
- Fiscal year end
- December
- Address
- 4400 Chatterton Way, Victoria, BC, Canada, V8X 5J3
- Phone
- 604-362-3654
- Website
- asepmedical.com
About Asep Medical Holdings Inc
ASEP Medical Holdings Inc., together with its subsidiaries, engages in the acquisition of research and development assets, technologies, and businesses in the area of life sciences and medical diagnostics. It offers peptide technologies that cover therapeutic applications, including bacterial biofilm infections, anti-inflammatory, antibiotic synergy, and immune modulating; diagnostic kits for predicting the onset of severe sepsis; and medical devices with anti-microbial and antifouling coating. The company was formerly known as Trenchant Life Sciences Investment Corp. and changed its name to ASEP Medical Holdings Inc. in November 2021. ASEP Medical Holdings Inc. was incorporated in 2021 and is headquartered in Victoria, Canada.
Asep Medical Holdings Inc management
2- Dr. Richard Heinzl M.D.Interim CEO & Chairman of the Board · born 1965
- Ms. Jacqueline M. Tucker F.C.A., FCPAChief Financial Officer · born 1956